U.S. stocks steady; Cook’s dismissal, Nvidia earnings in spotlight
In a recent transaction involving Werewolf Therapeutics , Inc. (NASDAQ:HOWL), significant shareholder Ansbert Gadicke executed a sale of 4,386 shares of the company’s common stock. The shares were sold at a price of $1.05 each, resulting in a total transaction value of $4,605. The sale comes amid a challenging period for the company, whose stock has declined 86% over the past year. According to InvestingPro analysis, the company, currently valued at $40.3 million, appears undervalued relative to its Fair Value. This sale was part of a broader activity on March 27, 2025, where Gadicke also exercised warrants to acquire 50,873 shares at a price of $0.09 per share, paid on a cashless basis.
Following these transactions, Gadicke’s holdings in the company amount to 6,718,670 shares. The shares are held through various entities, including MPM (BVMF:ESPA3) Asset Management LLC and UBS Oncology Impact Fund L.P., among others. The transactions reflect ongoing investment activities by Gadicke and related entities, who are significant stakeholders in Werewolf Therapeutics.
In other recent news, Werewolf Therapeutics has maintained its Market Outperform rating from JMP analysts, with a stable price target of $4.00. The company has made progress in its clinical trials by selecting a recommended dose for its WTX-124 drug, aimed at treating melanoma, renal cell carcinoma, and cutaneous squamous cell carcinoma. An interim data update is anticipated in the fourth quarter of 2025, which will provide insights into the drug’s efficacy and safety. Werewolf Therapeutics also plans to engage with the FDA in the second half of 2025 to discuss potential accelerated approval pathways for WTX-124.
Additionally, Werewolf Therapeutics has announced changes to its board of directors. Dr. Derek DiRocco resigned from the board, and Dr. Anil Singhal has been appointed as a new board member. Dr. Singhal brings over three decades of experience in the biopharmaceutical industry, having held leadership roles at Trishula Therapeutics, Adicet Bio, and AbbVie (NYSE:ABBV). His appointment includes serving on the company’s Audit Committee and receiving an option to purchase 45,000 shares of the company’s stock. These developments reflect Werewolf Therapeutics’ ongoing efforts in advancing its clinical programs and strengthening its leadership team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.